New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases

Advances in Experimental Medicine and Biology

Volumn 535, Issue , 2002, Pages 219-226

  Butters, T D ^a   Dwek, R A ^a   Platt, F M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; GLUCOSYLCERAMIDASE; GLYCOLIPID; GLYCOSPHINGOLIPID; MIGLUSTAT; URIDINE DIPHOSPHATE GLUCOSE;

BLOOD BRAIN BARRIER; CATABOLISM; CELL CULTURE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME REPLACEMENT; EUKARYOTE; GAUCHER DISEASE; GLYCOSYLATION; HEMATOLOGICAL PARAMETERS; HUMAN; IC 50; KNOCKOUT GENE; LIVER SIZE; LYSOSOME STORAGE DISEASE; MONOGENIC DISORDER; NONHUMAN; ORGAN SIZE; PALLIATIVE THERAPY; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; SPLEEN; TAY SACHS DISEASE; TREATMENT OUTCOME;

1-DEOXYNOJIRIMYCIN; ANIMALS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GAUCHER DISEASE; GLYCOSPHINGOLIPIDS; HUMANS; LYSOSOMAL STORAGE DISEASES; MICE;

EUKARYOTA;

EID: 1642481152     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (32)

1. Allende, M.L. and Proia, R.L., 2002, Lubricating cell signaling pathways with gangliosides, Curr Opin Struct Biol. 12:587-592.
2. Andersson, U., Butters, T.D., Dwek, R.A., and Platt, F.M., 2000, N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo, Biochem Pharmacol. 59:821-829.
3. Butters, T.D., Dwek, R.A., and Platt, F.M., 2000a, Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders, Chem Rev. 100:4683-4696.
4. Butters, T.D., Dwek, R.A., and Platt, F.M., 2003a, therapeutic applications of imino sugars in lysosomal storage disorders, Curr Top Med Chem. 3:561-574.
5. Butters, T.D., Mellor, H.R., Narita, K., Dwek, R.A., and Platt, F.M., 2003b, Small Molecule Therapeutics for the Treatment of Glycolipid Lysosomal Storage Disorders, Phil Trans R Soc Lond B 358:927-945.
6. Butters, T.D., van den Broek, L.A.G.M., Fleet, G.W.J., Krulle, T.M., Wormald, M.R., Dwek, R.A., and Platt, F.M., 2000b, Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis, Tetrahedron:Asymmetry. 11:113-124.
7. Cox, T., Lachmann, R., Hollak, C., Aerts, J., van Weely, S., Hrebicek, M., Platt, F., Butters, T., Dwek, R., Moyses, C., Gow, I., Elstein, D., and Zimran, A., 2000, Novel oral treatment of Gaucher's Disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis, Lancet. 355:1481-1485.
8. Dwek, R.A., Butters, T.D., Platt, F.M., and Zitzmann, N., 2002, targeting glycosylation as a therapeutic approach, Nature Rev Drug Discovery. 1:65-75.
9. Freeze, H.H., 2002, Human disorders in N-glycosylation and animal models, BBA Gen Subjects. 1573:388-393.
10. Gadola, S.D., Zaccai, N.R., Harlos, K., Shepherd, D., CastroPalomino, J.C., Ritter, G., Schmidt, R.R., Jones, E.Y., and Cerundolo, V., 2002, Structure of human CD1b with bound ligands at 2.3 angstrom, a maze for alkyl chains, Nat Immunol. 3:721-726.
11. Gagnon, M. and Saragovi, H.U., 2002, Gangliosides: therapeutic agents or therapeutic targets?, Expert Opin Ther Patents. 12:1215-1223.
12. Jeyakumar, M., Butters, T.D., CortinaBorja, M., Hunnam, V., Proia, R.L., Perry, V.H., Dwek, R.A., and Platt, F.M., 1999, Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin, Proc Nat Acad Sci USA. 96:6388-6393.
13. Jeyakumar, M., Butters, T.D., Dwek, R.A., and Platt, F.M., 2002a, Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis, Neuropathol Appl Neurobiol. 28:343-357.
14. Jeyakumar, M., Norflus, F., Tifft, C.J., CortinaBorja, M., Butters, T.D., Proia, R.L., Perry, V.H., Dwek, R.A., and Platt, F.M., 2001, Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation, Blood. 97:327-329.
15. Jeyakumar, M., Smith, D., EliottSmith, E., CortinaBorja, M., Reinkensmeier, G., Butters, T.D., Lemm, T., Sandhoff, K., Perry, V.H., Dwek, R.A., and Platt, F.M., 2002b, An inducible mouse model of late onset Tay-Sachs disease, Neurobiol Disease. 10:201-210.
16. Kobayashi, T. and Hirabayashi, V., 2000, Lipid membrane domains in cell surface and vacuolar systems, Glycoconjugate J. 17:163-171.
17. Kolter, T. and Sandhoff, K., 1999, Sphingolipids - their metabolic pathways and the pathobiochemistry of neurodegenerative diseases, Angew Chem Int Ed. 38:1532-1568.
18. Marek, K.W., Vijay, I.K., and Marth, J.D., 1999, A recessive deletion in the GlcNAc-1-phosphotransferase gene results in peri-implantation embryonic lethality, Glycobiology. 9:1263-1271.
19. Marks, D.L., Wu, K.J., Paul, P., Kamisaka, Y., Watanabe, R., and Pagano, R.E., 1999, Oligomerization and topology of the Golgi membrane protein glucosylceramide synthase, J Biol Chem. 274:451-456.
20. Mellor, H.R., Nolan, J., Pickering, L., Wormald, M.R., Platt, F.M., Dwek, R.A., Fleet, G.W.J., and Butters, T.D., 2002, Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycins, Biochem J. 366:225-233.
21. Platt, F.M. and Butters, T.D., 1998, New therapeutic prospects for the glycosphingolipid lysosomal storage diseases, Biochem Pharmacol. 56:421-430.
22. Platt, F.M. and Butters, T.D., 2000, Substrate deprivation: A new therapeutic approach for the glycosphingolipid lysosomal storage diseases, Expert Reviews in Molecular Medicine (http://www-ermm.cbcu.cam.ac.uk) 1-17.
23. Platt, F.M., Neises, G.R., Dwek, R.A., and Butters, T.D., 1994a, N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis, J Biol Chem. 269:8362-8365.
24. Platt, F.M., Neises, G.R., Karlsson, G.B., Dwek, R.A., and Butters, T.D., 1994b, N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing, J Biol Chem. 269:27108-27114.
25. Platt, F.M. Neises, G.R., Reinkensmeier, G., Townsend, M.J., Perry, V.H., Proia, R.L., Winchester, B., Dwek, R.A., and Butters, T.D., 1997a, Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin, Science. 276:428-431.
26. Platt, F.M., Reinkensmeier, G., Dwek, R.A., and Butters, T.D., 1997b, Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin, J Biol Chem. 272:19365-19372.
27. Priestman, D.A., Platt, F.M., Dwek, R.A., and Butters, T.D., 2000, Imino sugar therapy for type 1 Gaucher disease, Glycobiology. 19:iv-vi.
28. Sawkar, A.R., Cheng, W.C., Beutler, E., Wong, C.H., Balch, W.E., and Kelly, J.W., 2002, Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease, Proc Nat Acad Sci USA. 99:15428-15433.
29. Suzuki, K., Proia, R.L., and Suzuki, K., 1998, Mouse models of human lysosomal diseases, Brain Path. 8:195-215.
30. Yamashita, T., Wada, R., Sasaki, T., Deng, C.X., Bierfreund, U., Sandhoff, K., and Proia, R.L., 1999, A vital role for glycosphingolipid synthesis during development and differentiation, Proc Nat Acad Sci USA. 96:9142-9147.
31. Zimran, A., 1997, Gaucher's Disease, London, Bailliere Tindall.
32. Zimran, A. and Elstein, D., 2003, Gaucher disease and the clinical experience with substrate reduction therapy, Phil Trans R Soc Lond B 358:961-966. 226